H.C. Wainwright Reaffirms UroGen Pharma Buy Rating Following UGN-103 NDA Filing

H.C. Wainwright has reaffirmed its Buy rating and $75.00 price target on UroGen Pharma (NASDAQ:URGN) following the company’s submission of a New Drug Application to the FDA for UGN-103. Analyst Ram Selvaraju maintained his bullish stance on the biotechnology company, citing strong clinical data and extended market exclusivity as key drivers for the stock’s continued The post H.C. Wainwright…